medmix AG (MEDX) Fair Value & Analysis
Industrials · CH · Market cap CHF 337M
Fair value as of: Aug 13, 2026
From 24 valuation models · updated yesterday
Share price +10.1% over the past month.
A solid business, but screening 64% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (CHF 4.13). The favourable scenario is already priced in.
- Solid but not exceptional quality (54/100) and above fair value, neither a clear bargain nor a standout compounder.
- A fairly wide model range (CHF 2.01 to CHF 4.13) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
58‑month range CHF 7.79 – CHF 42.05 · fair‑value band CHF 2.01 – CHF 4.13 · the CHF 9.17 price screens above the CHF 3.30 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.
Analysis
medmix AG (MEDX) currently trades at CHF 9.17, while our model-based Fair Value estimate is CHF 3.30, implying the stock looks roughly 64.0% overvalued today. The Quality Score stands at 54/100 (solid quality), in the Industrials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, medmix AG generated revenue of CHF 448M at a net margin of 1.4%. Revenue declined 8.3% year over year. It earns a return on equity of 1.6%. Net debt stands at CHF 286M. Fundamentals as of Aug 13, 2026
Our scenario range runs from CHF 2.01 (bear case) to CHF 4.13 (bull case); at CHF 9.17, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 29% below its 52-week high and 14% above its 52-week low, currently below its 200-day average. For context, the median of 10 Industrials peers we cover trades at -46% fair-value upside, at -64%, MEDX screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: Asset-Based (CHF 7.01) versus Earnings-Based (CHF 1.35). Highest evidence: Growth DCF (80).
Notify me when MEDX reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 52 · Market factors (momentum, volatility) 38
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
medmix AG designs, produces, and sells high-precision devices and services in Switzerland and internationally. It operates through the Healthcare, and Consumer and Industrial segments.
Full company description
medmix AG designs, produces, and sells high-precision devices and services in Switzerland and internationally. It operates through the Healthcare, and Consumer and Industrial segments. The company offers dispensers, cartridges, mixers, tips, syringes, pen, and auto injectors for delivery of dental materials; delivery devices and mixing for bone repair and tissue treatment, which are used for prosthetics, restoratives, anesthetics, and aesthetics; the pen and auto injectors, which are used in fertility and growth hormone treatments, treatment of diabetes, osteoporosis, and other diseases; and the delivery and mixing devices, which are used by tissue banks and medical device OEMs. It also produces and markets dispensers, cartridges, and mixers for two-component adhesives and sealants for use in construction, transportation, electronics, infrastructure, and general industrial sectors; and micro-brushes and applicators for eyes, eyelashes, lips, and facial make-up. The company offers its products under the Mixpac, Transcodent, Qiaoyi, Cox, MK, Medmix, Haselmeier, and Geka brands. medmix AG was founded in 1922 and is based in Baar, Switzerland.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
medmix AG reported revenue of CHF 448M in FY2025 versus CHF 457M in FY2021, a compound −0.5%/yr. Reported net income was CHF 6.4M in FY2025, compounding −38.2%/yr from FY2021.
MEDX screens 64% overvalued. Compare with GE Vernova Inc →
Peer Group
Specialty Industrial Machinery · 807 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Specialty Industrial Machinery median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Specialty Industrial Machinery stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| GE Vernova Inc 1GEV | €899.80 | €186.93 | -79% |
| 1SIE 1SIE | €281.75 | €91.93 | -67% |
| SMNS SMNS | C$31.76 | C$22.75 | -28% |
| Atlas Copco AB ATCOA | kr 210.00 | kr 112.59 | -46% |
| Sandvik AB SAND | kr 358.60 | kr 193.01 | -46% |
| Zhejiang Sanhua Intelligent Controls Co 002050 | ¥39.17 | ¥22.68 | -42% |
| NARI Technology Co 600406 | ¥24.06 | ¥18.71 | -22% |
| ABB India Limited ABB | ₹7,700 | ₹1,322 | -83% |
| Cummins India Limited CUMMINSIND | ₹5,315 | ₹1,355 | -75% |
| Bharat Heavy Electricals Limited BHEL | ₹420.00 | ₹96.51 | -77% |
Compare medmix AG with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Industrials stocks →
Frequently asked questions
Is medmix AG (MEDX) overvalued or undervalued?
What is the fair value of MEDX?
What is the quality score of MEDX?
What is the revenue of medmix AG (MEDX)?
What is the net profit margin of MEDX?
Does medmix AG pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track medmix AG and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.